PHILADELPHIA, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of Ionis Pharmaceuticals, Inc. (“Ionis” or the “Company”) (NASDAQ: IONS) following the Company’s November 9, 2026 announcement substantially reducing its full-year 2026 sales forecast for TRYNGOLZA (olezarsen).

On November 9, 2026, Ionis announced that it was lowering its 2026 TRYNGOLZA sales guidance from $100 million–$110 million to approximately $50 million, citing a slower-than-anticipated commercial launch.

Previously, Ionis had expressed confidence in TRYNGOLZA's commercial launch and its ability to achieve the Company's sales guidance. The November 9, 2026, disclosures raise questions concerning whether Ionis adequately disclosed adverse sales trends and commercialization challenges known to management during the third quarter.

On this news, the stock price of Ionis was down more than 25% during intraday trading on November 9, 2026.

Ionis (IONS) Investors: Contact Kehoe Law Firm

If you purchased or otherwise acquired Ionis securities and suffered financial losses, you are encouraged to contact Kehoe Law Firm or Michael Yarnoff, Esq., (215) 792-6676, Ext. 804, myarnoff@kehoelawfirm.com, info@kehoelawfirm.com, to learn more about the investigation and receive a free, no-obligation evaluation of potential legal claims.

ABOUT KEHOE LAW FIRM, P.C.

Kehoe Law Firm, P.C. is a nationally recognized, plaintiff-side class action law firm representing investors, consumers, and employees in matters involving securities fraud, corporate misconduct, mergers and acquisitions, antitrust violations, whistleblower claims, data breaches, consumer fraud, employment law violations, as well as ERISA and retirement plan litigation. Its attorneys have served as lead or co-lead counsel in major securities cases, recovering more than $10 billion for institutional and individual investors.

Attorney Advertising